Vascular disruptive agent OXi4503 and anti-angiogenic agent Sunitinib combination treatment prolong survival of mice with CRC liver metastasis

Lignende værker

• Treatment with the vascular disruptive agent OXi4503 induces an immediate and widespread epithelial to mesenchymal transition in the surviving tumor
  af: Fifis, Theodora, et al.
  Udgivet: (2013)
• Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer
  af: Bothwell, Katelyn D., et al.
  Udgivet: (2016)
• Spatial morphological and molecular differences within solid tumors may contribute to the failure of vascular disruptive agent treatments
  af: Nguyen, Linh, et al.
  Udgivet: (2012)
• Dual Targeting of Tumor Vasculature: Combining Avastin and Vascular Disrupting Agents (CA4P or OXi4503)
  af: Siemann, Dietmar W., et al.
  Udgivet: (2008)
• Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
  af: Cummings, J, et al.
  Udgivet: (2012)